Information on the EAMS scientific opinion given to pembrolizumab for metastatic non-small cell lung cancer (NSCLC), including the public assessment report.
This positive scientific opinion was issued to MSD Ltd for pembrolizumab for the treatment of metastatic non-small cell lung cancer (NSCLC).
The scientific opinion includes:
- a public assessment report
- a treatment protocol:
- for healthcare professionals
- for patients
- on the pharmacovigilance system